Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma

NCT01594125 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: Nintedanib high dose
DRUG: Nintedanib low dose
DRUG: Nintedanib medium dose
DRUG: Nintedanib medium dose
DRUG: Nintedanib high dose

Sponsor

Boehringer Ingelheim